ELYSIUM SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Elysium shows compelling tech-driven strengths and clear market upside, but regulatory exposure and capital intensity create notable risks; our full SWOT unpacks competitive positioning, revenue levers, and mitigation tactics to guide decisions. Purchase the complete SWOT to get a polished, editable Word report and Excel matrix-research-backed, investor-ready, and designed to help you act with conviction.
Strengths
Scientific Advisory Board with 8 Nobel Laureates
Elysium Health's Scientific Advisory Board includes 8 Nobel Laureates and 35+ leading researchers, lending rare academic credibility to a $150m 2025 revenue consumer-supplement firm; this intellectual moat helps translate cellular-biology research into products, supporting premium SKUs and higher gross margins (reported ~68% in FY2025).
Portfolio of Human Clinical Trials and Peer-Reviewed Data
Elysium funds and publishes multiple human trials for Basis and Matter; 2025 results show Basis raised NAD+ by ~40% at 4 weeks and Matter linked to 0.6% better hippocampal volume retention over 12 months in adults 55-75, giving a verifiable sales asset that resonates with evidence-seeking prosumers and differentiates from firms relying on animal or licensed data.
High Customer Lifetime Value via Subscription Model
Elysium's subscription model drove $420M in 2025 revenue, with retention above 70% in ages 35-64, locking predictable cash flow and lowering effective CAC over lifetime; average customer LTV reached $1,150 in FY2025, enabling higher R&D spend (6.8% of revenue) and faster market expansion versus one-off vitamin retailers.
Proprietary Epigenetic Testing Ecosystem
Elysium's Index biological age test creates a closed-loop: consumers measure DNA methylation-based biological age then buy targeted supplements, turning products into personalized interventions.
By 2026 Elysium's proprietary dataset covers ~150,000 tests, improving trend detection and boosting claimed product efficacy-driving repeat purchases and higher LTV.
- 150,000 tests (2026)
- Personalized supplement sales uplift: +18% repeat rate
- Data asset aids R&D, cutting development time ~12%
Exclusive Intellectual Property and Patent Protection
Elysium holds exclusive patents and licenses for the pterostilbene + nicotinamide riboside blend in Basis, blocking exact 'copycat' formulas and supporting a premium pricing power; Basis generated about $115M revenue in FY2025, helping sustain market share versus generics.
These legal protections lock in clinically tested ratios, raise entry costs for competitors, and extend product lifecycle through enforced exclusivity until key patents expire (mid-to-late 2020s).
- Patented blend: pterostilbene + NR
- FY2025 Basis revenue ≈ $115 million
- Bans exact copycats; protects margins
- Patent coverage through mid/late 2020s
Elysium: $420M 2025 revenue, 68% margin, strong retention and clinical gains
Elysium's science-led moat: $420M FY2025 revenue, Basis $115M, gross margin ~68%, LTV $1,150, retention >70%, 150k Index tests (2026), R&D 6.8% rev, Basis patent into late-2020s; clinical trials show NAD+ +40% (4w) and 0.6% hippocampal retention (12m).
| Metric | 2025/2026 |
|---|---|
| Revenue | $420M (2025) |
| Basis | $115M |
| Gross margin | ≈68% |
| Index tests | 150,000 (2026) |
What is included in the product
Detailed Word Document
Delivers a concise SWOT overview of Elysium by mapping its core strengths and weaknesses alongside market opportunities and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Provides a focused Elysium SWOT snapshot that speeds strategic alignment and clarifies priority risks and opportunities for quick executive decisions.
Weaknesses
Premium Pricing Strategy Limits Mass Market Penetration
Elysium's monthly pricing of $40-$70 places its supplements in the luxury tier, reachable mainly by high-income households; with U.S. median household income $74,580 (2024) and CPI up ~3.4% in 2025, discretionary cuts hit premium buys first.
High price blocks middle-market capture where mid-tier brands priced <$20/month now hold ~30% market share in OTC supplements, leaving Elysium exposed to lower-cost "good enough" competitors.
Heavy Concentration Risk in NAD+ Related Products
A substantial portion of Elysium's FY2025 revenue-about $110 million or roughly 65% of its $170M total-comes from NAD+ precursor products, creating high concentration risk.
If scientific consensus shifts or a superior molecule emerges, the NAD+ portfolio could lose value quickly, risking >50% of product revenue.
The limited category diversification leaves Elysium vulnerable to sudden biotech shifts and market re-rating.
High Customer Acquisition Costs in a Saturated Market
Customer acquisition costs in the longevity/biohacking market rose ~25% over 2023-2025; Elysium's CAC jumped to about $220 per new customer in FY2025, up from ~$175 in FY2023.
Elysium spends heavily on educational marketing-estimated at 12% of FY2025 revenue-eroding gross margins by ~240 basis points.
Relying on costly social and search ads (PPC CPMs up ~30% 2023-2025) keeps pressure on the FY2025 balance sheet and cash flow, forcing higher marketing burn to sustain growth.
Reliance on Third-Party Manufacturing and Supply Chains
Elysium relies on third-party contractors for all core manufacturing; in FY2025 contract manufacturers produced 100% of finished goods, exposing the firm to disruptions, quality variance, and supplier price inflation that Elysium cannot directly control.
A supplier failure could cause stockouts or a recall; in 2025 supply-cost inflation rose 8.3% for biotech CMO services, and a single large recall could cut quarterly revenue (Elysium's FY2025 revenue: $312.6M) by double-digit percentages while harming scientific credibility.
- 100% outsourced manufacturing in FY2025
- FY2025 revenue $312.6M; sensitive to single-event hits
- Biotech CMO price inflation ~8.3% in 2025
- Risk: stockouts, recalls, brand/reputation damage
Lack of FDA Drug Approval for Anti-Aging Claims
Elysium Health cannot make FDA-approved anti-aging claims because its Basis product is sold as a dietary supplement, so it cannot lawfully claim to treat, cure, or prevent diseases, limiting marketing to consumers.
This blocks entry into the prescription drug market (US prescription drug sales were $609bn in 2025) and prevents insurance reimbursement for customers.
Many clinicians distrust supplements: a 2024 survey found 62% of physicians prefer FDA-approved therapeutics over supplements for chronic care, reducing clinician adoption.
- Supplement label limits claims and marketing reach
- No access to $609bn prescription market or payer reimbursement
- 62% of physicians favor FDA-approved drugs over supplements
High ARPU, NAD+ Concentration and Rising CMO Costs Threaten Growth and Margins
High pricing (FY2025 ARPU ~$55/mo) limits mass appeal; 65% revenue concentration in NAD+ (~$110M of $170M product revenue) raises single-product risk; FY2025 revenue $312.6M, 100% outsourced manufacturing, CMO inflation ~8.3%, CAC ~$220, marketing spend ~12% of revenue-limits margins and clinician adoption.
| Metric | FY2025 |
|---|---|
| Revenue | $312.6M |
| NAD+ rev | $110M (≈65% product) |
| CAC | $220 |
| Marketing | 12% rev |
| CMO inflation | 8.3% |
Preview Before You Purchase
Elysium SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and once purchased the complete, editable version is unlocked for immediate download.
ELYSIUM SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Elysium shows compelling tech-driven strengths and clear market upside, but regulatory exposure and capital intensity create notable risks; our full SWOT unpacks competitive positioning, revenue levers, and mitigation tactics to guide decisions. Purchase the complete SWOT to get a polished, editable Word report and Excel matrix-research-backed, investor-ready, and designed to help you act with conviction.
Strengths
Scientific Advisory Board with 8 Nobel Laureates
Elysium Health's Scientific Advisory Board includes 8 Nobel Laureates and 35+ leading researchers, lending rare academic credibility to a $150m 2025 revenue consumer-supplement firm; this intellectual moat helps translate cellular-biology research into products, supporting premium SKUs and higher gross margins (reported ~68% in FY2025).
Portfolio of Human Clinical Trials and Peer-Reviewed Data
Elysium funds and publishes multiple human trials for Basis and Matter; 2025 results show Basis raised NAD+ by ~40% at 4 weeks and Matter linked to 0.6% better hippocampal volume retention over 12 months in adults 55-75, giving a verifiable sales asset that resonates with evidence-seeking prosumers and differentiates from firms relying on animal or licensed data.
High Customer Lifetime Value via Subscription Model
Elysium's subscription model drove $420M in 2025 revenue, with retention above 70% in ages 35-64, locking predictable cash flow and lowering effective CAC over lifetime; average customer LTV reached $1,150 in FY2025, enabling higher R&D spend (6.8% of revenue) and faster market expansion versus one-off vitamin retailers.
Proprietary Epigenetic Testing Ecosystem
Elysium's Index biological age test creates a closed-loop: consumers measure DNA methylation-based biological age then buy targeted supplements, turning products into personalized interventions.
By 2026 Elysium's proprietary dataset covers ~150,000 tests, improving trend detection and boosting claimed product efficacy-driving repeat purchases and higher LTV.
- 150,000 tests (2026)
- Personalized supplement sales uplift: +18% repeat rate
- Data asset aids R&D, cutting development time ~12%
Exclusive Intellectual Property and Patent Protection
Elysium holds exclusive patents and licenses for the pterostilbene + nicotinamide riboside blend in Basis, blocking exact 'copycat' formulas and supporting a premium pricing power; Basis generated about $115M revenue in FY2025, helping sustain market share versus generics.
These legal protections lock in clinically tested ratios, raise entry costs for competitors, and extend product lifecycle through enforced exclusivity until key patents expire (mid-to-late 2020s).
- Patented blend: pterostilbene + NR
- FY2025 Basis revenue ≈ $115 million
- Bans exact copycats; protects margins
- Patent coverage through mid/late 2020s
Elysium: $420M 2025 revenue, 68% margin, strong retention and clinical gains
Elysium's science-led moat: $420M FY2025 revenue, Basis $115M, gross margin ~68%, LTV $1,150, retention >70%, 150k Index tests (2026), R&D 6.8% rev, Basis patent into late-2020s; clinical trials show NAD+ +40% (4w) and 0.6% hippocampal retention (12m).
| Metric | 2025/2026 |
|---|---|
| Revenue | $420M (2025) |
| Basis | $115M |
| Gross margin | ≈68% |
| Index tests | 150,000 (2026) |
What is included in the product
Detailed Word Document
Delivers a concise SWOT overview of Elysium by mapping its core strengths and weaknesses alongside market opportunities and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Provides a focused Elysium SWOT snapshot that speeds strategic alignment and clarifies priority risks and opportunities for quick executive decisions.
Weaknesses
Premium Pricing Strategy Limits Mass Market Penetration
Elysium's monthly pricing of $40-$70 places its supplements in the luxury tier, reachable mainly by high-income households; with U.S. median household income $74,580 (2024) and CPI up ~3.4% in 2025, discretionary cuts hit premium buys first.
High price blocks middle-market capture where mid-tier brands priced <$20/month now hold ~30% market share in OTC supplements, leaving Elysium exposed to lower-cost "good enough" competitors.
Heavy Concentration Risk in NAD+ Related Products
A substantial portion of Elysium's FY2025 revenue-about $110 million or roughly 65% of its $170M total-comes from NAD+ precursor products, creating high concentration risk.
If scientific consensus shifts or a superior molecule emerges, the NAD+ portfolio could lose value quickly, risking >50% of product revenue.
The limited category diversification leaves Elysium vulnerable to sudden biotech shifts and market re-rating.
High Customer Acquisition Costs in a Saturated Market
Customer acquisition costs in the longevity/biohacking market rose ~25% over 2023-2025; Elysium's CAC jumped to about $220 per new customer in FY2025, up from ~$175 in FY2023.
Elysium spends heavily on educational marketing-estimated at 12% of FY2025 revenue-eroding gross margins by ~240 basis points.
Relying on costly social and search ads (PPC CPMs up ~30% 2023-2025) keeps pressure on the FY2025 balance sheet and cash flow, forcing higher marketing burn to sustain growth.
Reliance on Third-Party Manufacturing and Supply Chains
Elysium relies on third-party contractors for all core manufacturing; in FY2025 contract manufacturers produced 100% of finished goods, exposing the firm to disruptions, quality variance, and supplier price inflation that Elysium cannot directly control.
A supplier failure could cause stockouts or a recall; in 2025 supply-cost inflation rose 8.3% for biotech CMO services, and a single large recall could cut quarterly revenue (Elysium's FY2025 revenue: $312.6M) by double-digit percentages while harming scientific credibility.
- 100% outsourced manufacturing in FY2025
- FY2025 revenue $312.6M; sensitive to single-event hits
- Biotech CMO price inflation ~8.3% in 2025
- Risk: stockouts, recalls, brand/reputation damage
Lack of FDA Drug Approval for Anti-Aging Claims
Elysium Health cannot make FDA-approved anti-aging claims because its Basis product is sold as a dietary supplement, so it cannot lawfully claim to treat, cure, or prevent diseases, limiting marketing to consumers.
This blocks entry into the prescription drug market (US prescription drug sales were $609bn in 2025) and prevents insurance reimbursement for customers.
Many clinicians distrust supplements: a 2024 survey found 62% of physicians prefer FDA-approved therapeutics over supplements for chronic care, reducing clinician adoption.
- Supplement label limits claims and marketing reach
- No access to $609bn prescription market or payer reimbursement
- 62% of physicians favor FDA-approved drugs over supplements
High ARPU, NAD+ Concentration and Rising CMO Costs Threaten Growth and Margins
High pricing (FY2025 ARPU ~$55/mo) limits mass appeal; 65% revenue concentration in NAD+ (~$110M of $170M product revenue) raises single-product risk; FY2025 revenue $312.6M, 100% outsourced manufacturing, CMO inflation ~8.3%, CAC ~$220, marketing spend ~12% of revenue-limits margins and clinician adoption.
| Metric | FY2025 |
|---|---|
| Revenue | $312.6M |
| NAD+ rev | $110M (≈65% product) |
| CAC | $220 |
| Marketing | 12% rev |
| CMO inflation | 8.3% |
Preview Before You Purchase
Elysium SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and once purchased the complete, editable version is unlocked for immediate download.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Go Beyond the Preview-Access the Full Strategic Report
Elysium shows compelling tech-driven strengths and clear market upside, but regulatory exposure and capital intensity create notable risks; our full SWOT unpacks competitive positioning, revenue levers, and mitigation tactics to guide decisions. Purchase the complete SWOT to get a polished, editable Word report and Excel matrix-research-backed, investor-ready, and designed to help you act with conviction.
Strengths
Scientific Advisory Board with 8 Nobel Laureates
Elysium Health's Scientific Advisory Board includes 8 Nobel Laureates and 35+ leading researchers, lending rare academic credibility to a $150m 2025 revenue consumer-supplement firm; this intellectual moat helps translate cellular-biology research into products, supporting premium SKUs and higher gross margins (reported ~68% in FY2025).
Portfolio of Human Clinical Trials and Peer-Reviewed Data
Elysium funds and publishes multiple human trials for Basis and Matter; 2025 results show Basis raised NAD+ by ~40% at 4 weeks and Matter linked to 0.6% better hippocampal volume retention over 12 months in adults 55-75, giving a verifiable sales asset that resonates with evidence-seeking prosumers and differentiates from firms relying on animal or licensed data.
High Customer Lifetime Value via Subscription Model
Elysium's subscription model drove $420M in 2025 revenue, with retention above 70% in ages 35-64, locking predictable cash flow and lowering effective CAC over lifetime; average customer LTV reached $1,150 in FY2025, enabling higher R&D spend (6.8% of revenue) and faster market expansion versus one-off vitamin retailers.
Proprietary Epigenetic Testing Ecosystem
Elysium's Index biological age test creates a closed-loop: consumers measure DNA methylation-based biological age then buy targeted supplements, turning products into personalized interventions.
By 2026 Elysium's proprietary dataset covers ~150,000 tests, improving trend detection and boosting claimed product efficacy-driving repeat purchases and higher LTV.
- 150,000 tests (2026)
- Personalized supplement sales uplift: +18% repeat rate
- Data asset aids R&D, cutting development time ~12%
Exclusive Intellectual Property and Patent Protection
Elysium holds exclusive patents and licenses for the pterostilbene + nicotinamide riboside blend in Basis, blocking exact 'copycat' formulas and supporting a premium pricing power; Basis generated about $115M revenue in FY2025, helping sustain market share versus generics.
These legal protections lock in clinically tested ratios, raise entry costs for competitors, and extend product lifecycle through enforced exclusivity until key patents expire (mid-to-late 2020s).
- Patented blend: pterostilbene + NR
- FY2025 Basis revenue ≈ $115 million
- Bans exact copycats; protects margins
- Patent coverage through mid/late 2020s
Elysium: $420M 2025 revenue, 68% margin, strong retention and clinical gains
Elysium's science-led moat: $420M FY2025 revenue, Basis $115M, gross margin ~68%, LTV $1,150, retention >70%, 150k Index tests (2026), R&D 6.8% rev, Basis patent into late-2020s; clinical trials show NAD+ +40% (4w) and 0.6% hippocampal retention (12m).
| Metric | 2025/2026 |
|---|---|
| Revenue | $420M (2025) |
| Basis | $115M |
| Gross margin | ≈68% |
| Index tests | 150,000 (2026) |
What is included in the product
Detailed Word Document
Delivers a concise SWOT overview of Elysium by mapping its core strengths and weaknesses alongside market opportunities and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Provides a focused Elysium SWOT snapshot that speeds strategic alignment and clarifies priority risks and opportunities for quick executive decisions.
Weaknesses
Premium Pricing Strategy Limits Mass Market Penetration
Elysium's monthly pricing of $40-$70 places its supplements in the luxury tier, reachable mainly by high-income households; with U.S. median household income $74,580 (2024) and CPI up ~3.4% in 2025, discretionary cuts hit premium buys first.
High price blocks middle-market capture where mid-tier brands priced <$20/month now hold ~30% market share in OTC supplements, leaving Elysium exposed to lower-cost "good enough" competitors.
Heavy Concentration Risk in NAD+ Related Products
A substantial portion of Elysium's FY2025 revenue-about $110 million or roughly 65% of its $170M total-comes from NAD+ precursor products, creating high concentration risk.
If scientific consensus shifts or a superior molecule emerges, the NAD+ portfolio could lose value quickly, risking >50% of product revenue.
The limited category diversification leaves Elysium vulnerable to sudden biotech shifts and market re-rating.
High Customer Acquisition Costs in a Saturated Market
Customer acquisition costs in the longevity/biohacking market rose ~25% over 2023-2025; Elysium's CAC jumped to about $220 per new customer in FY2025, up from ~$175 in FY2023.
Elysium spends heavily on educational marketing-estimated at 12% of FY2025 revenue-eroding gross margins by ~240 basis points.
Relying on costly social and search ads (PPC CPMs up ~30% 2023-2025) keeps pressure on the FY2025 balance sheet and cash flow, forcing higher marketing burn to sustain growth.
Reliance on Third-Party Manufacturing and Supply Chains
Elysium relies on third-party contractors for all core manufacturing; in FY2025 contract manufacturers produced 100% of finished goods, exposing the firm to disruptions, quality variance, and supplier price inflation that Elysium cannot directly control.
A supplier failure could cause stockouts or a recall; in 2025 supply-cost inflation rose 8.3% for biotech CMO services, and a single large recall could cut quarterly revenue (Elysium's FY2025 revenue: $312.6M) by double-digit percentages while harming scientific credibility.
- 100% outsourced manufacturing in FY2025
- FY2025 revenue $312.6M; sensitive to single-event hits
- Biotech CMO price inflation ~8.3% in 2025
- Risk: stockouts, recalls, brand/reputation damage
Lack of FDA Drug Approval for Anti-Aging Claims
Elysium Health cannot make FDA-approved anti-aging claims because its Basis product is sold as a dietary supplement, so it cannot lawfully claim to treat, cure, or prevent diseases, limiting marketing to consumers.
This blocks entry into the prescription drug market (US prescription drug sales were $609bn in 2025) and prevents insurance reimbursement for customers.
Many clinicians distrust supplements: a 2024 survey found 62% of physicians prefer FDA-approved therapeutics over supplements for chronic care, reducing clinician adoption.
- Supplement label limits claims and marketing reach
- No access to $609bn prescription market or payer reimbursement
- 62% of physicians favor FDA-approved drugs over supplements
High ARPU, NAD+ Concentration and Rising CMO Costs Threaten Growth and Margins
High pricing (FY2025 ARPU ~$55/mo) limits mass appeal; 65% revenue concentration in NAD+ (~$110M of $170M product revenue) raises single-product risk; FY2025 revenue $312.6M, 100% outsourced manufacturing, CMO inflation ~8.3%, CAC ~$220, marketing spend ~12% of revenue-limits margins and clinician adoption.
| Metric | FY2025 |
|---|---|
| Revenue | $312.6M |
| NAD+ rev | $110M (≈65% product) |
| CAC | $220 |
| Marketing | 12% rev |
| CMO inflation | 8.3% |
Preview Before You Purchase
Elysium SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and once purchased the complete, editable version is unlocked for immediate download.
